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Background: Enterovirus 71 (EV71), one of the most important neurotropic EVs, has caused death and long-term
neurological sequelae in hundreds of thousands of young children in the Asia-Pacific region in the past decade.
The neurological diseases are attributed to infection by EV71 inducing an extensive peripheral and central nervous
system (CNS) inflammatory response with abnormal cytokine production and lymphocyte depletion induced by
EV71 infection. In the absence of specific antiviral agents or vaccines, an effective immunosuppressive strategy
would be valuable to alleviate the severity of the local inflammation induced by EV71 infection.
Presentation of the hypothesis: The complement system plays a pivotal role in the inflammatory response.
Inappropriate or excessive activation of the complement system results in a severe inflammatory reaction or
numerous pathological injuries. Previous studies have revealed that EV71 infection can induce complement
activation and an inflammatory response of the CNS. CR2-targeted complement inhibition has been proved to be a
potential therapeutic strategy for many diseases, such as influenza virus-induced lung tissue injury, postischemic
cerebral injury and spinal cord injury. In this paper, a mouse model is proposed to test whether a recombinant
fusion protein consisting of CR2 and a region of Crry (CR2-Crry) is able to specifically inhibit the local complement
activation induced by EV71 infection, and to observe whether this treatment strategy can alleviate or even cure the
neurogenic inflammation.
Testing the hypothesis: CR2-Crry is expressed in CHO cells, and its biological activity is determined by
complement inhibition assays. 7-day-old ICR mice are inoculated intracranially with EV71 to duplicate the
neurological symptoms. The mice are then divided into two groups, in one of which the mice are treated with
CR2-Crry targeted complement inhibitor, and in the other with phosphate-buffered saline. A group of mice
deficient in complement C3, the breakdown products of which bind to CR2, are also infected with EV71 virus. The
potential bioavailability and efficacy of the targeted complement inhibitor are evaluated by histology,
immunofluorescence staining and radiolabeling.
Implications of the hypothesis: CR2-Crry-mediated targeting complement inhibition will alleviate the local
inflammation and provide an effective treatment for the severe neurological diseases associated with EV71
infection.* Correspondence: hongbinsong@263.net; ywang7508@yahoo.com.cn;
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Enterovirus 71 (EV71) is the major causative agent of
hand-foot-and-mouth disease (HFMD) [1]. Since the vir-
tual eradication of the poliovirus, EV71 has been recog-
nized as the most important neurotropic EV. It can
cause various neurological diseases, such as aseptic men-
ingitis, acute flaccid paralysis, brainstem encephalitis and
fatal neurogenic pulmonary edema [2,3].
Since the first identification of EV71 in 1969, several
epidemic outbreaks have been reported in the Asia-
Pacific region (Malaysia in 1997, Australia in 1999,
Singapore in 2000, Japan in 1997 and 2000, Taiwan in
1998, 2000, 2001 and 2002, and Mainland China in
1998, 2004 and 2008) [3-6]. There were more than 1.1
million HFMD cases including 353 deaths due to the
neurological disease in China in 2009 [7]. Mortality was
particularly high in EV71-induced brainstem encephalitis
complicated with pulmonary edema, especially in chil-
dren under 5 years of age. EV71 infection has therefore
become an important public health problem in the
world, particularly in the Asia-Pacific region. EV71 dis-
played genetic diversity and the virus circulating in this
region underwent rapid evolutionary change [8,9], which
hampered the development of antiviral agents and vac-
cines for EV71 infection. As currently no specific anti-
viral agents or vaccines are available, we should seek a
new therapeutic approach to alleviate the severity of
EV71-induced neurological diseases.
Presentation of the hypothesis
EV71 is involved in the inflammatory response of the
central nervous system
In recent EV71 epidemics in the Asia-Pacific region, the
serious complications were mainly associated with the
central nervous system (CNS), and the primary lethal
symptom was neurogenic pulmonary edema [10]. Mag-
natic Resonance Imaging and autopsy examinations
showed that the pathological lesions occurred predomin-
antly in the brainstem and the spinal cord, rather than
in the lung or heart [1,11]. The EV71-associated inflam-
matory response was found mainly in the CNS region
but not in other organs of EV71-infected patients
[2,3,12], indicating that the CNS is the major target of
EV71 infection. EV71 can enter the CNS through per-
ipheral nerves via retrograde axonal neuronal transmis-
sion way or via viremic spread through the blood–brain
barrier (BBB). It then induces the human immune cell
lines and triggers NF-кь activation to produce proin-
flammatory cytokines leading to an inflammatory re-
sponse of the CNS [2,3,10]. Besides, many molecules,
such as cyclooxygenase-2 and its metabolite, the cellular
protein Cdk5 and others, can facilitate EV71 replication
in neural cells and induce neural apoptotic cell death
[3]. It is now widely accepted that the extensiveperipheral and CNS inflammatory response accompanied
by the excessive release of cytokines and chemokines is re-
sponsible for the pathogenesis of EV71-associated neuro-
logical diseases. These can cause neuronal degeneration,
CNS necrosis and destruction of vasomotor function in
the brainstem, leading to autonomic nervous system dys-
regulation and even fatal neurogenic pulmonary edema
[13-16]. Patients with brainstem encephalitis and neuro-
genic pulmonary edema showed elevated levels of inflam-
matory CNS cytokines, including TNF-α, IL-1β, and IL-6,
IL-10, IL-13 and IFN-γ, and a marked depletion of CD4+
and CD8+ T cells and NK cells [1,11,14], demonstrating
the correlation between the extensive CNS inflammatory
response and EV71-associated neurological diseases.
Inflammatory injury induced by invading pathogens is
associated with complement activation
Complement is a key system for immune surveillance
and homeostasis, and it bridges the innate and acquired
immune responses [17,18]. Under normal circumstances,
the immune response recognizes, attacks and eliminates
the invading pathogens and this response is beneficial
for the host. However, inappropriate or excessive activa-
tion of the complement system can result in severe in-
flammation or tissue injury involved in numerous
pathological conditions. Previous studies have noted that
many diseases, including the neurological diseases
known as transmissible spongiform encephalopathies
(TSEs), are due to inflammatory injury. This injury
occurs as a result of immune activation by the invading
pathogens, instead of being directly induced by the
pathogens themselves. TSEs are fatal, neurodegenerative
diseases caused by prion protein PrPSc. PrPSc present in
the brain can activate complement, and the deposited
complement components C1q, C3b and the membrane-
attack complex have all been detected in the brains of
patients with prion disease, the pathology of which is due
to the propagation of inflammation [19]. It has been proved
that an excessive inflammatory reaction in lung tissues
induced by influenza virus infection is closely related to
complement activation, and complement activation can ser-
iously influence the severity of lung injury [18,20].
The detailed pathogenesis of enteroviruses including
EV71 remains unclear, but it has been documented that
enterovirus infection can induce an extensive peripheral
and CNS inflammatory response [3,11,14]. Our previous
results have proved that the complement components
C1q and C3 are observed as obvious depositions in the
brainstems of mice showing the neurological symptoms
of EV71 infection (data not shown), indicating that the
inflammatory response in the mouse CNS is associated
with complement activation. Anderson et al. showed
that coxsackievirus B3 (CVB3) capsid proteins could
interact with complement C3 and activate the alternative
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The research conducted by Shih et al. revealed that EV71
infection could lead to an increased level of mRNAs encod-
ing complement proteins [22]. These results also illustrated
the activation of complement due to EV71 infection.
Targeted complement inhibition is a potential therapeutic
strategy for the inflammatory response
Complement activation can generate inflammatory pro-
ducts including C2a, C3a, C4a and C5a which mediate tis-
sue injury [18,23]. C3a and C5a have the functions of
anaphylatoxins and chemoattractants with a wide range of
bioactive properties which can induce and increase the in-
flammatory reaction [24,25]. Complement proteins on cell
membranes can be receptors for activated complement
proteins or proteins that regulate complement. Comple-
ment receptor 2 (CR2), a member of the C3 binding pro-
tein family, serves as an important interface between the
complement system and adaptive immunity. The specific
ligands for CR2 are iC3b, C3dg and C3d, all being cell-
bound breakdown fragments of C3 which are deposited on
the complement-activating cell surface [24,26,27]. Thus,
CR2 is a rational target for the delivery of complement
inhibitors such as Crry and CD59 to inflammatory sites
that have been induced by complement activation. As Crry
has different levels of species selectivity and acts as an im-
portant complement regulatory protein, it is considered as
an effective complement inhibitor which can regulate com-
plement activation by inhibiting the activity of C3/C5 con-
vertase. CR2-Crry, an ideal targeted inhibitor which has
shown increased bioavailability and efficacy and decreased
immunosuppression [18,27,28], could provide an appropri-
ate therapeutic strategy for many inflammation-related
diseases such as lung tissue injury induced by influenza
virus, postischemic cerebral injury and spinal cord injury.
Hypothesis
Previous studies indicated that CR2-Crry had an appropri-
ate bioavailability for targeted complement inhibition for
the treatment of spinal cord injury and cerebral ischemia/
reperfusion injury [27,28]. Our experiments also proved
that CR2-Crry could obviously inhibit the pulmonary in-
flammatory response caused by influenza virus [18]. Thus,
targeted complement inhibition induced by CR2-Crry may
be an effective therapeutic strategy for EV71 infection of
the CNS. Complement activation is a double-edged sword
leading to both physiological defense and pathological
damage, and systematic complement inhibition may result
in potential side effects including infection [25]. Thus, a
new treatment strategy for EV71 infection is required.
Here, the complement inhibitor CR2-Crry, which targets
the sites of complement activation, is proposed as a spe-
cific inhibitor of local complement activation without
causing severe systemic side effects.Testing the hypothesis
The recombinant fusion protein CR2-Crry is prepared by
joining the mouse CR2 sequence to the sequence encod-
ing the extracellular region of mouse Crry, and is
expressed and purified as described previously [26,29].
The biological activity of the recombinant CR2-Crry is
characterized by complement inhibition assays. 7-day-old
ICR mice are inoculated intracranially with EV71 BrCr
strain to duplicate the neurological symptoms. Then the
mice are divided into two groups, in one of which the
mice are treated with CR2-Crry, and in the other with
phosphate-buffered saline. A group of mice deficient in
complement C3 are also each infected with EV71 virus.
Animals are perfused transcardially with isotonic saline
followed by 4% paraformaldehyde. The brains and spinal
cords are either frozen for cryosectioning or processed in
paraffin. Immunofluorescence staining is used to assess
the presence of complement component C3 and CR2-
Crry in the sites of inflammatory, and radiolabeling is con-
ducted to detect the tissue distribution of 125I-labeled
CR2-Crry in control mice and in mice infected with EV71.
Implications of the hypothesis
Since the outbreak of HFMD in Shandong and Anhui pro-
vinces in 2008, EV71 is gradually spreading to other pro-
vinces of China and has become a serious threat to public
health in these regions. The EV71-associated neurological
diseases which often cause deaths in children under 5
years of age are not directly induced by the virus itself, but
are attributable to the inflammation due to EV71 infec-
tion. Whilst antiviral therapy is one possible approach, it
is perhaps more important to inhibit the inflammatory re-
sponse caused by EV71. Compared with systemic inhib-
ition, CR2-mediated targeting complement inhibition
should greatly reduce the inflammatory reaction or tissue
injury resulting from excess complement activation. Thus,
verification of the current hypothesis could lead to an ef-
fective treatment for EV71 infection.
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